CAMP4 to Participate in Upcoming Investor Conferences

Group 1 - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression and restore healthy protein levels [1][4] - The company will participate in several upcoming investor conferences, including Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 12, 2025, and the Leerink Partners Global Healthcare Conference on March 10, 2025 [1][2] - CAMP4's proprietary RAP Platform™ allows for the mapping of regRNAs and the generation of therapeutic candidates aimed at treating over 1,200 genetic disorders where a modest increase in protein expression could be clinically meaningful [4] Group 2 - The company is developing disease-modifying treatments for a wide range of rare and prevalent genetic diseases, emphasizing the importance of increasing healthy protein levels for therapeutic benefits [4] - The upcoming presentations will be accessible via webcasts, with replays available for 30 days following the events [3]